Small Biotechs Like Aastrom Biosciences and Geron Likely to Benefit From New Patent System
09 May 2012 - 10:20PM
Marketwired
In recent months the Biotech Industry has become a hotbed of Merger
and Acquisition (M&A) activity and speculation. As large
pharmaceuticals face major patent expirations in 2012 they have
looked to biotech companies to provide new streams of revenue.
Given the limited amount of quality companies, the ones with
quality drugs and proven technologies stand to gain the most. Five
Star Equities examines the outlook for companies in the Biotech
Industry and provides equity research on Aastrom Biosciences, Inc.
(NASDAQ: ASTM) and Geron Corporation (NASDAQ: GERN).
Access to the full company reports can be found at:
www.FiveStarEquities.com/ASTM
www.FiveStarEquities.com/GERN
The U.S. patent system will see a major change for the first
time in over 60 years. The America Invents Act (AIA) will see the
U.S. patent system transform from a "first to invent" to a "first
to file" system. The majority of countries around the world have
already adopted the "first to file" system. The AIA will help
benefit biotech companies "by enhancing patent quality and the
efficiency, objectivity, predictability and transparency of the
U.S. patent system," BIO President and CEO Jim Greenwood stated in
a press release. "Small biotechnology companies rely heavily on
their patents to attract investment," and "they will benefit from
the improvements to our nation's patent system made by this
legislation," added Greenwood.
Five Star Equities releases regular market updates on the
Biotech Industry so investors can stay ahead of the crowd and make
the best investment decisions to maximize their returns. Take a few
minutes to register with us free at www.FiveStarEquities.com and
get exclusive access to our numerous stock reports and industry
newsletters.
Aastrom Biosciences is the leader in developing
patient-specific, expanded multicellular therapies for use in the
treatment of patients with severe, chronic cardiovascular diseases.
The company's proprietary cell-processing technology enables the
manufacture of ixmyelocel-T, a patient-specific multicellular
therapy expanded from a patient's own bone marrow and delivered
directly to their damaged tissues.
Geron is a biopharmaceutical company developing first-in-class
therapies for cancer. The company has two lead product candidates
in clinical development, imetelstat and GRN1005. The company
recently announced that it has completed planned enrollment of its
randomized Phase 2 clinical trial of imetelstat, a telomerase
inhibitor, as maintenance therapy following platinum-based
induction therapy for patients with advanced non-small cell lung
cancer (NSCLC).
Five Star Equities provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. Five Star Equities has not been compensated by any of the
above-mentioned companies. We act as an independent research portal
and are aware that all investment entails inherent risks. Please
view the full disclaimer at:
www.FiveStarEquities.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Five Star Equities Email Contact
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024